Evommune (EVMN) Assets (2024 - 2026)

Evommune (EVMN) posted quarterly Assets of $322.5 million for Q1 2026, up 43.35% quarter-over-quarter from $224.9 million in Q4 2025.

Analysis

Evommune (EVMN) Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Assets for 3 consecutive years, with $322.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Assets changed N/A year-over-year to $322.5 million; the TTM figure through Mar 2026 stood at $322.5 million (changed N/A YoY), while the FY2025 annual figure was $224.9 million, up 195.77% from the prior year.
Assets grew to $322.5 million in Q1 2026 per EVMN's latest filing, from $224.9 million in the prior quarter.
Across five years, Assets topped out at $322.5 million in Q1 2026 and bottomed at $76.1 million in Q4 2024.
Historically, Assets has averaged $177.0 million across 3 years, with a median of $154.7 million in 2025.
On a YoY basis, Assets climbed as much as 195.77% in 2025 and fell as far as 195.77% in 2025.
Evommune's Assets stood at $76.1 million in 2024, then jumped by 195.77% to $224.9 million in 2025, then soared by 43.35% to $322.5 million in 2026.
Business Quant data shows EVMN's Assets at $322.5 million in Q1 2026, $224.9 million in Q4 2025, and $84.5 million in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	139.27 Bn	131.42 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	63.45 Bn	58.27 Bn	1.37 Bn	10.03 Bn
4	Moderna	57.73 Bn	52.59 Bn	52.00 Mn	10.96 Bn
5	Revolution Medicines	44.08 Bn	44.08 Bn	-	4.32 Bn
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	9.18 Bn
7	Alnylam Pharmaceuticals	35.14 Bn	31.84 Bn	992.69 Mn	5.56 Bn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	19.82 Bn
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	2.10 Bn
10	Evommune	443.38 Mn	242.59 Mn	-	301.95 Mn

Historic Data

Download Data